Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-beta2

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-beta2

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabedersen (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Isarna Therapeutics

    • Most Recent Events

    • 28 Dec 2022 According to an Oncotelic Therapeutics media release, data from the trial were presented at the SITC Conference.
    • 28 Sep 2022 Results published in the Oncotelic Therapeutics Media Release.
    • 12 Jul 2022 According to an Oncotelic Therapeutics media release, data from this study were presented at the 7th JCA-AACR Special Joint Conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top